Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/12241121/
——————————————————————
J Neurooncol. 2002 Sep;59(3):239-42
——————————————————————
http://www.ncbi.nlm.nih.gov/m/pubmed/12241121/
——————————————————————
Journal of Neuro-Oncology
Volume 59, Issue 3 , pp 239-242
——————————————————————
http://link.springer.com/article/10.1023%2FA%3A1019905127442
——————————————————————
DOI
10.1023/A:1019905127442
Journal of Neuro-Oncology 59: 239–242, 2002
2002 Kluwer Academic Publishers. Printed in the Netherlands
——————————————————————
Click to access Baker_Complete_response_of_GBM_with_Phenylbutyrate_2002.pdf
——————————————————————
Neuro-Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
======================================
REFERENCES:
======================================
6. Gore SD, SAMID D, Weng LJ: Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 3(10): 1755–1762, 1997
——————————————————————
7. Ram Z, SAMID D, Walbridge S, Oshiro EM, Viola JJ, Tao-Cheng JH, Shack S, Thibault A, Myers CE, Oldfield EH: Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 54: 2923–2927, 1994
——————————————————————
8. Thibault A, SAMID D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE: Phase I study of phenylacetate administration twice daily to patients with cancer. Cancer 75: 2932–2938, 1995
——————————————————————
9. SAMID D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE: Phenylacetate and phenylbutyrate as novel, non-toxic differentiation inducers. Adv Exp Med Biol 400A: 501–505, 1997
——————————————————————
10. Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C, Prados MD: Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17(3): 984–990, 1999
SAMID D References
——————————————————————
11. Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD: Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 74(6): 641–642, 1999
——————————————————————
12. SAMID D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE: Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 54: 891–895, 1994
======================================
Antineoplastons: Phenylacetylglutaminate (PG or PAG), Phenylacetate (PN), and Phenylbutyrate (PB):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/17/phenylacetylglutaminate-pg-or-pag-phenylacetate-pn-and-phenylbutyrate-pb/
======================================
Phenylbutyrate (PB):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/18/phenylbutyrate-pb/
======================================
Phenylacetate (PN):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/18/phenylacetate-pn/
======================================
Phenylacetylglutamine (PG or PAG):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/18/phenylacetylglutamine-pg-or-pag/
======================================
Burzynski, China, and Dvorit D. Samid:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/02/21/burzynski-china-dvorit-d-samid/
======================================
Critiquing: Dr. David H. “Orac” Gorski and The Skeptics™ http://www.scienceblogs.com/Insolence
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/08/critiquing-dr-david-h-orac-gorski-and-the-skeptics/
======================================